⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Supplementary Figure S3 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Tony Georgiev Sara Puglioli Lucrezia Principi Ettore Gilardoni Christian Pellegrino Gabriele Bassi Andrea Galbiati Dario Neri Samuele Cazzamalli

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study reveals promising results for PSMA-targeted drug conjugates in treating prostate cancer.
Key evidence includes detailed analysis of chromatograms from small molecule-drug conjugates.
Assessment using liquid chromatography investigates the peptidase-cleavable linker in drug design.
These findings suggest potential advancements in targeted cancer therapies for improved treatment outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis of PSMA-targeted therapies shows promise in treating prostate cancer, highlighting the role of drug conjugates.

Abstract

LC chromatogram of I3

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Georgiev et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a68 https://doi.org/10.1158/1535-7163.30255230

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
2Supplementary Figure S2 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
3Supplementary Figure S4 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
4Supplementary Figure S5 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
5Supplementary Figure S6 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025

More related papers

Supplementary Figure S8 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary FIgure S7 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S11 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025